The ICAM1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human hepatocellular carcinoma cell line, engineered to disrupt the gene encoding intercellular adhesion molecule 1 (ICAM1). This heterogeneous pool of targeted cells provides a physiologically relevant loss-of-function model for investigating ICAM1-dependent mechanisms in a tumor microenvironment context. The polyclonal format preserves genetic diversity while eliminating functional ICAM1 expression, enabling robust experimental comparisons without the clonal artifacts associated with single-cell-derived lines. Researchers can employ this tool to dissect leukocyte adhesion, transendothelial migration, and downstream signaling events with high reproducibility.
The parental SK-HEP-1 cell line originated from the ascitic fluid of a patient with liver adenocarcinoma, establishing it as a well-characterized model for hepatocellular carcinoma. These epithelial-like cells display features of malignant hepatocytes and are widely used in cancer biology research to study tumor progression, metastasis, and cell adhesion dynamics. The SK-HEP-1 background offers a biologically appropriate platform for examining ICAM1 function, given the molecule’s role in mediating cellular interactions that contribute to tumor invasiveness and immune evasion.
ICAM1 is a transmembrane glycoprotein that functions as a key adhesion receptor, binding to leukocyte integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) to promote firm cell-cell adhesion and diapedesis. Its expression is transcriptionally upregulated by pro-inflammatory cytokines such as TNF-alpha, IL-1, and IFN-gamma through activation of NF-kB, AP-1, and STAT transcription factors. Upon engagement, ICAM1 triggers intracellular signaling cascades involving Src kinase, focal adhesion kinase (FAK), and the PI3K/Akt and MAPK/ERK pathways, which collectively regulate cytoskeletal reorganization, cell migration, and inflammatory gene expression. The receptor also interacts with CD43, fibrinogen, hyaluronan, and rhinovirus capsid proteins, highlighting its multifaceted role in immune responses and pathogen entry.
In the SK-HEP-1 tumor cell context, disruption of ICAM1 attenuates critical adhesion-dependent processes. Knockout cells exhibit reduced leukocyte binding and impaired transendothelial migration, directly reflecting the molecule’s function in leukocyte trafficking. Furthermore, because ICAM1-mediated signaling contributes to the invasive and metastatic potential of carcinoma cells, these polyclonal knockout cells enable studies on how ICAM1 loss modulates tumor cell behavior, including altered migration and invasion. The model is particularly valuable for dissecting the interplay between inflammatory stimuli and tumor progression through pathways such as NF-kB and PI3K/Akt, which are aberrantly active in hepatocellular carcinoma.
Typical research applications include quantitative leukocyte adhesion and transendothelial migration assays, where ICAM1 knockout SK-HEP-1 cells serve as a negative control to confirm specificity. The cells are ideally suited for drug screening targeting anti-inflammatory or anti-metastatic compounds, as well as for investigating ICAM1-mediated signaling through techniques like flow cytometry, Western blotting, and RNA-seq. Additional phenotypic assays??such as scratch wound healing and Boyden chamber migration??elucidate the impact of ICAM1 loss on cell motility. Cytokine stimulation experiments further reveal how upstream regulators like TNF-alpha modulate residual cellular responses. For further technical details or customized applications, please contact Ascent Research.
